Pandorum Technologies is a Bengaluru-based biotechnology company developing programmable regenerative medicines and engineered human tissues. Founded in 2011, its platform combines biomaterials, cellular engineering, designer exosomes and biofabrication to promote tissue repair and regeneration. Its lead therapeutic, Kuragenx, is a cell-free exosome-based treatment for severe corneal diseases and has received US FDA Orphan Drug Designation. Pandorum also develops 3D human liver organoids for drug research and regenerative approaches for lung and other tissues. The company operates R&D activities in India and the United States and collaborates with clinical and manufacturing partners including Northwestern Medicine, Medical University of South Carolina and Nucelion Therapeutics.
Pandorum offers scientists and engineers the opportunity to work on clinical-stage regenerative medicine spanning designer exosomes, stem-cell biology, biomaterials, organoids and advanced biofabrication. Its lead therapy Kuragenx has received US FDA Orphan Drug Designation, and the company raised an $18 million Series B in 2026 to advance clinical development and global manufacturing. Pandorum also collaborates with clinical and manufacturing organizations in India and the US. Its careers page lists health and life insurance, family medical coverage, annual health checks, mental-health support and competitive compensation, while emphasizing continuous learning. Candidates should also consider the long validation, regulatory and clinical-development cycles inherent to biotechnology.
Regenerative Therapeutics
Cellular Engineering
Cellular Engineering
Tissue Engineering
Biofabrication
Biofabrication
Biofabrication
Biomaterials
Biomaterials
Cellular Engineering
Cellular Engineering
Live Cell Imaging
Live Cell Imaging
Co-founder, CEO and Director. Bhowmick holds a PhD from the Indian Institute of Science and completed postdoctoral research at the European Molecular Biology Laboratory as an EMBO-Marie Curie fellow. His expertise includes biophysics, biomaterials, structural biology, protein biochemistry and computational biology.
Co-founder, CTO and Director. Chandru completed research in Aerospace Engineering at the Indian Institute of Science, where he received a gold medal for best thesis. His expertise spans systems engineering, advanced manufacturing and biofabrication. He was named to Forbes Asia's 30 Under 30 Healthcare & Science list in 2016.
Advises Pandorum on commercialization and strategic partnerships. Ranganathan has more than three decades of healthcare experience and previously served as Managing Director of Allergan India and Associate Vice President at Allergan International, with expertise in ophthalmology, medical devices and healthcare commercialization.
BioSpectrum India
Pandorum and Bharat Biotech subsidiary Nucelion Therapeutics expanded their manufacturing partnership to support two PRIP-backed ophthalmology programs targeting advanced keratopathy and wet age-related macular degeneration. The programs use Pandorum's designer-exosome regenerative-medicine platform.
Read articleET Pharma
Pandorum closed an $18 million Series B round to advance clinical development of Kuragenx and other tunable exosome-based therapies, expand manufacturing capacity and grow operations across the United States, Japan and the Middle East.
Read articleBusiness Wire
Pandorum partnered with Nucelion Therapeutics to build manufacturing capabilities for its exosome-based ocular regenerative therapies across Asia-Pacific, supporting clinical development, regional supply and regulatory readiness.
Read articlePandorumBengaluru, India
PandorumBengaluru, India
PandorumDelhi, India
PandorumBengaluru, India
PandorumBengaluru, India
PandorumBengaluru, India
PandorumBengaluru, India
